

## Product datasheet for **TR310626**

### PAFAH1B3 Human shRNA Plasmid Kit (Locus ID 5050)

#### Product data:

Product Type:	shRNA Plasmids
Product Name:	PAFAH1B3 Human shRNA Plasmid Kit (Locus ID 5050)
Locus ID:	5050
Synonyms:	PAFAHG
Vector:	pRS (TR20003)
E. coli Selection:	Ampicillin
Mammalian Cell Selection:	Puromycin
Format:	Retroviral plasmids
Components:	PAFAH1B3 - Human, 4 unique 29mer shRNA constructs in retroviral untagged vector(Gene ID = 5050). 5µg purified plasmid DNA per construct 29-mer scrambled shRNA cassette in pRS Vector, TR30012, included for free.
RefSeq:	<a href="#">NM_001145939</a> , <a href="#">NM_001145940</a> , <a href="#">NM_002573</a> , <a href="#">NM_002573.1</a> , <a href="#">NM_002573.2</a> , <a href="#">NM_002573.3</a> , <a href="#">NM_001145939.1</a> , <a href="#">NM_001145940.1</a> , <a href="#">BC003016</a> , <a href="#">BC007863</a> , <a href="#">NM_002573.4</a>
UniProt ID:	<a href="#">Q15102</a>
Summary:	This gene encodes an acetylhydrolase that catalyzes the removal of an acetyl group from the glycerol backbone of platelet-activating factor. The encoded enzyme is a subunit of the platelet-activating factor acetylhydrolase isoform 1B complex, which consists of the catalytic beta and gamma subunits and the regulatory alpha subunit. This complex functions in brain development. A translocation between this gene on chromosome 19 and the CDC-like kinase 2 gene on chromosome 1 has been observed, and was associated with cognitive disability, ataxia, and atrophy of the brain. Alternatively spliced transcript variants have been described. [provided by RefSeq, Mar 2009]
shRNA Design:	These shRNA constructs were designed against multiple splice variants at this gene locus. To be certain that your variant of interest is targeted, please contact <a href="mailto:techsupport@origene.com">techsupport@origene.com</a> . If you need a special design or shRNA sequence, please utilize our <a href="#">custom shRNA service</a> .



[View online »](#)

**Performance  
Guaranteed:**

OriGene guarantees that the sequences in the shRNA expression cassettes are verified to correspond to the target gene with 100% identity. One of the four constructs at minimum are guaranteed to produce 70% or more gene expression knock-down provided a minimum transfection efficiency of 80% is achieved. Western Blot data is recommended over qPCR to evaluate the silencing effect of the shRNA constructs 72 hrs post transfection. To properly assess knockdown, the gene expression level from the included scramble control vector must be used in comparison with the target-specific shRNA transfected samples.

For non-conforming shRNA, requests for replacement product must be made within ninety (90) days from the date of delivery of the shRNA kit. To arrange for a free replacement with newly designed constructs, please contact Technical Services at [techsupport@origene.com](mailto:techsupport@origene.com). Please provide your data indicating the transfection efficiency and measurement of gene expression knockdown compared to the scrambled shRNA control (Western Blot data preferred).